Evidence map›Paper›PMID 21034678›Full record

ReviewDiscovery medicine2010

Some unmet challenges in the immunology of viral infections.

Barry T Rouse, Aron E Lukacher

Abstract readReview
In one paragraph

Review in Discovery medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Metabolomics Signatures of SARS-CoV-2 Infection.Advances in experimental medicine and biology · 2022
    Review
  3. Article
  4. Article
  5. Article
  6. Genetic disruption of CD8+ Treg activity enhances the immune response to viral infection.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Barry T RouseDepartment of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee 37996, USA. btr@utk.edu
Aron E Lukacher

Funding

Mechanisms of Herpetic KeratitisR01EY005093 · NEI · UNIVERSITY OF TENNESSEE KNOXVILLE · PI ROUSE, BARRY T. · 1985 to 2020
$7.8M
T regulatory Cells in HSV Immunity and ImmunopathologyR01AI063365 · NIAID · UNIVERSITY OF TENNESSEE KNOXVILLE · PI ROUSE, BARRY T. · 2006 to 2015
$3.5M
T CELL IMMUNITY TO POLYOMA VIRUS INDUCED TUMORSR01CA071971 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI LUKACHER, ARON ELIOT · 2001 to 2011
$3.0M
Analysis of MHC Class Ib-Restricted Polyoma Virus-Specific CD8 T CellsR01CA139220 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI LUKACHER, ARON ELIOT · 2009 to 2013
$1.6M
NCI NIH HHS R01 CA071971NCI NIH HHS R01 CA139220NCI NIH HHS R01 CA71971NEI NIH HHS R01 EY005093NEI NIH HHS R01 EY05093NIAID NIH HHS R01 AI063365NIAID NIH HHS R01 AI106336501
6 · The paper itself

Abstract

Viral immunology is a rapidly evolving field. Major strides have been made in our understanding of innate and adaptive immune responses to viruses, largely based on highly reductionistic animal infection models, but more recently in humans, with validation that fundamental immunological concepts do in fact translate into clinical science well. From these studies there has emerged an appreciation of the enormous complexity of the immune response to viral infections as well as the diverse array of strategies developed by viruses to deal with immune detection. In this review, we highlight some of the major challenges we face in unraveling this complexity and summarize current efforts under way to improve the efficacy of viral vaccines.

Indexed as

HepacivirusHIVHumansImmunity, InnateInfluenza A Virus, H1N1 SubtypeTreatment OutcomeVaccinationViral VaccinesVirus DiseasesVirusesViral Vaccines

Identifiers

PMID21034678
PMCPMC3884557

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.